[Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]

S N Chen; L G Qiu

doi:10.3760/cma.j.cn112138-20241008-00665

[Interpretation of risk stratification in guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]

Zhonghua Nei Ke Za Zhi. 2024 Dec 1;63(12):1175-1178. doi: 10.3760/cma.j.cn112138-20241008-00665.

[Article in Chinese]

Authors

S N Chen¹, L G Qiu²

Affiliations

¹ The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou215006, China.
² Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin300020, China Tianjin Institutes of Health Science, Tianjin301600, China.

PMID: 39622720
DOI: 10.3760/cma.j.cn112138-20241008-00665

Abstract

《中国多发性骨髓瘤诊治指南（2024年修订）》如期和大家见面。新版指南的“危险度分层部分”有较大修订，包括首次纳入第二次修订的国际分期体系（R2-ISS）；整合了逐渐被公认的多个高危因素，并将多发性骨髓瘤（MM）分为超高危、高危和标危三组。随着对MM预后因素的深入认识和新疗法的不断引入，可逐步实现对MM的精准分层和个体化治疗。本文将对危险度分层部分的更新内容进行详细解读。.

MeSH terms

China
Humans
Multiple Myeloma* / diagnosis
Multiple Myeloma* / therapy
Practice Guidelines as Topic
Prognosis
Risk Assessment
Risk Factors